West Pharmaceutical
638 hedge funds and large institutions have $16.9B invested in West Pharmaceutical in 2022 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 246 increasing their positions, 221 reducing their positions, and 83 closing their positions.
104% more call options, than puts
Call options by funds: $38.3M | Put options by funds: $18.8M
11% more repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 221
0.82% more ownership
Funds ownership: 91.88% → 92.7% (+0.82%)
3% less funds holding
Funds holding: 655 → 638 (-17)
11% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 83
18% less capital invested
Capital invested by funds: $20.6B → $16.9B (-$3.69B)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$153M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$72M |
| 3 |
DCP
Durable Capital Partners
Bethesda,
Maryland
|
+$56.5M |
| 4 |
Amundi
Paris,
France
|
+$42.3M |
| 5 |
Millennium Management
New York
|
+$41.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$724M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$88.6M |
| 3 |
IIM
INTECH Investment Management
West Palm Beach,
Florida
|
-$56.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$56.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$35.1M |
WST Hedge Fund Activity: Q3 2022 in Review
638 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2022, worth a combined $16.9B — down 18% from $20.6B a quarter earlier.
Sellers outnumbered buyers: 83 funds closed out of WST and 74 opened new positions — a net loss of 9 holders — while 221 trimmed existing stakes and 246 added.
The largest buyer was Bank of New York Mellon, adding an estimated $153M. The largest seller was T. Rowe Price Associates, cutting an estimated $724M.
- 638 institutional investors held West Pharmaceutical (WST) as of Q3 2022, down from 655 in Q2 2022.
- Funds reported $16.9B of West Pharmaceutical stock for Q3 2022, down 18% quarter-over-quarter.
- 74 funds opened new West Pharmaceutical positions in Q3 2022 and 83 closed out, a net change of -9 holders.
- The largest West Pharmaceutical buyer in Q3 2022 was Bank of New York Mellon, an estimated $153M added.
- The largest West Pharmaceutical seller in Q3 2022 was T. Rowe Price Associates, an estimated $724M sold.
Based on aggregated 13F filings for Q3 2022.